Genetic Engineering & Biotechnology NewsCancer Stem Cells “Hedge” Their Bets with Noncanonical SignalingGenetic Engineering & Biotechnology News"The targeted inhibition of the Hedgehog signaling pathway, used in combination with other standard tre… Continue reading
Vivex to Serve As Platinum Sponsor for 13th World Stem Cell SummitPR Newswire (press release)MIAMI, Jan. 22, 2018 /PRNewswire/ — Vivex Biomedical, Inc. is proud to announce their platinum sponsorship of the 13th World Stem Cell Summit (WSCS). The summ… Continue reading
STAT |
With Juno deal, Celgene bets on the future of CAR–T — and its own
STAT y acquiring Juno Therapeutics (JUNO 1) for $9 billion, Celgene (CELG 2) is making a bullish bet on genetically engineered cells known as CAR-Ts becoming a cornerstone of cancer treatment. The same strategic reasoning compelled Gilead Sciences (GILD 3… UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News With $9 Billion Juno Deal, Celgene Doubles Down on CancerBloomberg Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing tractionBioWorld Online Reuters –CNBC –Zacks Investment Research –Zacks Investment Research all 241 news articles » |
The Independent |
Synthetic medical marijuana could fuel Singapore’s future economy and create jobs
The Independent Developing synthetic medicinal cannabinoids in a laboratory would mean that there will be no need to grow marijuana plants, which are illegal in the country even for research and development purposes. Besides raising the bar of Singapore’s research … |